Elysium Pharmaceuticals
Elysium Pharmaceuticals, often referred to simply as Elysium, is a prominent player in the biopharmaceutical industry, headquartered in India. Founded in 2014, the company has rapidly established itself as a leader in developing innovative therapies aimed at addressing unmet medical needs, particularly in the fields of neurology and oncology. With a strong focus on research and development, Elysium Pharmaceuticals is dedicated to creating unique, high-quality products that leverage cutting-edge science. Their core offerings include advanced therapeutics designed to improve patient outcomes and enhance quality of life. Elysium's commitment to excellence has positioned it as a notable contender in the global market, with significant achievements in clinical trials and partnerships that underscore its reputation for innovation and efficacy.
DitchCarbon Score
How does Elysium Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Elysium Pharmaceuticals's score of 0 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Elysium Pharmaceuticals's reported carbon emissions
Elysium Pharmaceuticals, headquartered in India, currently does not have publicly available carbon emissions data or specific reduction targets. Without emissions figures, it is challenging to assess their carbon footprint or climate commitments. However, the absence of data may indicate a need for enhanced transparency in their environmental impact reporting. As the pharmaceutical industry increasingly prioritises sustainability, Elysium Pharmaceuticals may benefit from establishing clear climate commitments and reduction initiatives to align with industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Elysium Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
